GET DAILY SIGNALSBeyondSpring Inc. (BYSI): Can It Reach the +55% Move to $1.00?
Key Takeaways
- BYSI is the ticker for BeyondSpring Inc., a clinical-stage biopharmaceutical company developing Plinabulin for non-small cell lung cancer (NSCLC).
- The $1.00 target is not an analyst consensus; it reflects the Nasdaq minimum bid price compliance threshold, a widely discussed milestone for this sub-$1 stock.
- With shares trading near $0.65 in early November 2026, reaching $1.00 would require a very large gain of roughly 55%.
- There are essentially no current, credible analyst price targets; the most recent attributable target is a stale Robert W. Baird $1.25 figure from May 2023, which predates major restructuring.
- The strongest supports are a September 2026 FDA Fast Track designation and a non-dilutive strategic transaction funding the DUBLIN-4 confirmatory Phase 3 trial.
- The biggest risks are a tight cash runway, going-concern uncertainty, Nasdaq delisting pressure, and the binary nature of a single-asset oncology pipeline.
- For more detail on Major News, Today's Price Move, Forecast, and Earnings, explore the dedicated BeyondSpring pages.
- Investors seeking broader market ideas can also explore Trending AI Robots for AI-driven stock and ETF signal discovery.
Analyst Coverage and the $1.00 Benchmark
BeyondSpring does not currently have a meaningful, up-to-date analyst price target base. Coverage collapsed after the company's 2021 FDA setback, and most published figures are years old. The last attributable target is Robert W. Baird's $1.25, set in May 2023 after successive cuts from $11.00 and $4.00; it has not been refreshed through the leadership change and strategic restructuring of 2026. Third-party aggregators still display a roughly $1.25 "consensus" on some pages, but this reflects stale, low-count data rather than live research. Because no credible current consensus exists, the $1.00 figure used here is not an analyst price target. It is drawn from identifiable public discussion of Nasdaq's $1.00 minimum bid price rule, which the company has publicly flagged as a compliance requirement.
Current Market Position and the Path Ahead
Shares of BeyondSpring Inc. (NASDAQ: BYSI) traded between roughly $0.64 and $0.69 in early November 2026, within a 52-week range of about $0.42 to $2.44. A move to $1.00 would require a gain of approximately 55%, which is a very large move for any stock and especially steep for a micro-cap biotech trading below a dollar. The company has no approved products, so revenue is essentially nil, and the path to a higher price depends almost entirely on clinical milestones for Plinabulin, the lead asset. In September 2026 the FDA granted Fast Track designation for Plinabulin plus docetaxel in post-ICI non-squamous NSCLC, and BeyondSpring completed a transaction selling its China subsidiary stake to Biolin Investment in exchange for non-dilutive funding of the confirmatory DUBLIN-4 Phase 3 trial (about 442 planned patients). These steps improve the odds of reaching a value inflection, but they do not by themselves establish near-term upside. I also checked this using Tickeron’s AI Trend Prediction Engine to gauge momentum against peers.
Factors That Could Support Progress Toward the Target
Several verified factors could support a re-rating. The Fast Track designation provides closer FDA engagement and the potential for a rolling review, which can shorten time to a regulatory decision. The Biolin transaction shifts roughly half the DUBLIN-4 enrollment cost to an external funder, easing the company's financing burden without immediate share dilution. Earlier DUBLIN-3 Phase 3 data showed that adding Plinabulin to docetaxel roughly doubled two- and three-year survival rates and cut grade 4 neutropenia from 33% to 5%, an efficacy and safety profile management has highlighted at ASCO and other conferences. A positive interim analysis or additional partnering activity could materially reset sentiment toward a name with a market capitalization near $25 million.
Obstacles That Could Keep the Target Out of Reach
The obstacles are substantial. BeyondSpring reported roughly $6.5 million in cash and short-term investments as of June 30, 2026, against a net loss of about $12.4 million in the first half of the year, implying a runway measured in months and a likely need for further financing or dilution. Auditors have previously flagged going-concern risk, and the company has received Nasdaq noncompliance notices tied to its sub-$1 bid price, raising the possibility of delisting or a reverse stock split that could further pressure holders. The pipeline is concentrated in a single asset, making the investment thesis binary, and thin trading volume amplifies volatility. Any clinical delay, data miss, or financing overhang could keep the stock well below $1.00.
Technical Levels and Market Structure
BYSI trades below both its 50-day moving average near $0.66 and its 200-day moving average near $1.26, reflecting a sustained downtrend. The 52-week low near $0.42 is the key support zone, while the $0.65 to $0.70 area has acted as near-term resistance. The $1.00 level itself is a psychological and compliance threshold that has historically coincided with heavy selling pressure in penny stocks, since it marks the Nasdaq minimum bid requirement. A durable move above $1.00 would require a decisive break of both the declining trend and the $1.00 psychological level, likely on elevated volume. One thing that stands out here is how thin the volume makes these levels especially sensitive.
Time Horizon and Key Items to Watch
There is no reliable time horizon attached to the $1.00 objective, since it is a compliance threshold rather than a formal research target. Investors should watch DUBLIN-4 enrollment progress and any interim analysis update, quarterly cash balances and any financing or partnering announcements, and Nasdaq compliance correspondence. Upcoming earnings reports, beginning with the next quarterly release, will clarify whether the cash runway has changed. FDA interactions flowing from the Fast Track designation and additional data presentations at oncology conferences are also relevant catalysts. From what I see, tracking these milestones closely will be essential.
Incorporating Tickeron’s AI Daily Buy/Sell Signals
In my analysis of names like BYSI, I often turn to Tickeron’s AI Daily Buy/Sell Signals to monitor momentum shifts in real time. The tool applies artificial intelligence across thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on technical behavior and market conditions. For a thinly traded micro-cap, it helps surface changing trends more efficiently alongside fundamental work. I find it useful for identifying setups before they appear obvious on the chart and for tracking positions without replacing core research.
Final Assessment
Whether BeyondSpring can reach $1.00 depends less on valuation than on execution: advancing DUBLIN-4 toward a positive readout while securing enough capital to avoid excessive dilution and Nasdaq delisting. The roughly 55% move required from current levels is very large, and the stock carries the binary risk typical of a single-asset clinical biotech with a limited cash runway. The Fast Track designation and non-dilutive trial funding are genuine tailwinds, but the going-concern flag, sub-$1 bid-price noncompliance, and absence of a credible current analyst consensus all argue for caution. A move to $1.00 is possible under a favorable clinical and financing scenario, but it is far from assured and should not be treated as a forecast.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
BYSI in downward trend: price dove below 50-day moving average on November 05, 2026
BYSI moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend. In 38 of 42 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for BYSI moved out of overbought territory on November 03, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 23 similar instances where the indicator moved out of overbought territory. In 18 of the 23 cases, the stock moved lower in the following days. This puts the odds of a move lower at 78%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 39 of 44 cases where BYSI's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 89%.
The 10-day moving average for BYSI crossed bearishly below the 50-day moving average on October 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BYSI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
BYSI broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for BYSI entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 30, 2026. You may want to consider a long position or call options on BYSI as a result. In 73 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for BYSI just turned positive on October 30, 2026. Looking at past instances where BYSI's MACD turned positive, the stock continued to rise in 38 of 50 cases over the following month. The odds of a continued upward trend are 76%.
Following a +55.97% 3-day Advance, the price is estimated to grow further. Considering data from situations where BYSI advanced for three days, in 174 of 217 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 20 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.724) is normal, around the industry mean (3.498). P/E Ratio (-3.682) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (31.056) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. BYSI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BYSI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of cancer therapies
Industry Biotechnology